Max Peters1, Metha Maenhout2, Jochem R N van der Voort van Zyp3, Marinus A Moerland3, Maaike R Moman4, Lotte M G Steuten5, Marijke J H van Deursen3, Marco van Vulpen3. 1. Department of Radiation Oncology, University Medical Center Utrecht, The Netherlands. Electronic address: m.peters-10@umcutrecht.nl. 2. Department of Radiation Oncology, University Medical Center Utrecht, The Netherlands. Electronic address: M.maenhout@umcutrecht.nl. 3. Department of Radiation Oncology, University Medical Center Utrecht, The Netherlands. 4. Department of Radiology, Meander Medical Center, Amersfoort, The Netherlands. 5. Department of Health Technology and Services Research, University of Twente, Enschede, The Netherlands.
Abstract
PURPOSE: Whole-gland salvage for recurrent prostate cancer (PCa) shows high failure and toxicity rates. Early and adequate localization of recurrences enables focal salvage, thereby potentially improving functional outcomes, while maintaining cancer control. MATERIALS AND METHODS: Retrospective analysis yielded 20 focal salvage I125 brachytherapy patients for locally recurrent PCa after primary radiotherapy. Tumor was defined by multiparametric MRI and correspondence with transrectal biopsies. Dose data were obtained intra-operatively. The tumor was prescribed ⩾144 Gy. Toxicity was scored by the Common Terminology Criteria for Adverse Events version 4 (CTCAE-4). Biochemical failure (BF) was defined using the Phoenix criteria (PSA-nadir + 2.0 ng/ml). Quality of life (QoL) was measured by SF-36 Health Survey and European Organization of Research and Treatment of Cancer (EORTC) C30+3 and PR25 questionnaires. RESULTS: With a median follow-up of 36 months (range 10-45), six patients experienced BF, of which three had no initial response. Grade 3 genitourinary (GU) toxicity occurred in one patient (a urethral stricture). The five previously potent patients retained erectile function. QoL remained decreased with regard to urinary symptoms. CONCLUSION: Focal salvage I125 brachytherapy showed one grade 3 GU toxicity in the 20 treated patients. Biochemical response and QoL were acceptable.
PURPOSE: Whole-gland salvage for recurrent prostate cancer (PCa) shows high failure and toxicity rates. Early and adequate localization of recurrences enables focal salvage, thereby potentially improving functional outcomes, while maintaining cancer control. MATERIALS AND METHODS: Retrospective analysis yielded 20 focal salvage I125 brachytherapy patients for locally recurrent PCa after primary radiotherapy. Tumor was defined by multiparametric MRI and correspondence with transrectal biopsies. Dose data were obtained intra-operatively. The tumor was prescribed ⩾144 Gy. Toxicity was scored by the Common Terminology Criteria for Adverse Events version 4 (CTCAE-4). Biochemical failure (BF) was defined using the Phoenix criteria (PSA-nadir + 2.0 ng/ml). Quality of life (QoL) was measured by SF-36 Health Survey and European Organization of Research and Treatment of Cancer (EORTC) C30+3 and PR25 questionnaires. RESULTS: With a median follow-up of 36 months (range 10-45), six patients experienced BF, of which three had no initial response. Grade 3 genitourinary (GU) toxicity occurred in one patient (a urethral stricture). The five previously potent patients retained erectile function. QoL remained decreased with regard to urinary symptoms. CONCLUSION: Focal salvage I125 brachytherapy showed one grade 3 GU toxicity in the 20 treated patients. Biochemical response and QoL were acceptable.
Authors: O Pons-Llanas; J Burgos-Burgos; S Roldan-Ortega; A Conde-Moreno; F Celada-Alvarez; J C Ruiz-Martinez; F Lliso-Valverde; A Tormo-Micó; J Perez-Calatayud; J López-Torrecilla Journal: Rep Pract Oncol Radiother Date: 2020-07-05
Authors: D A Smit Duijzentkunst; M Peters; J R N van der Voort van Zyp; M A Moerland; M van Vulpen Journal: World J Urol Date: 2016-03-24 Impact factor: 4.226